Alamar Biosciences collaborates with SciLifeLab to further explore human illnesses
FREMONT, Calif., May 28, 2025 — Alamar Biosciences, a trailblazer in precision proteomics, is teaming up with SciLifeLab to propel the advancement of translational proteomics and expedite the discovery of disease biomarkers. This strategic collaboration aims to deepen understanding of disease biology, accelerate the development of early diagnostic tools, and ultimately transform the healthcare landscape.
Alamar Biosciences' proprietary NULISA Platform and ARGO HT System, known for ultra-sensitive, multiplexed protein analysis from biofluids, pair with SciLifeLab's extensive data resources and proteomics capabilities, including the Human Protein Atlas, a comprehensive research program mapping the human proteome. The union of these powerful technologies is set to revolutionize the field.
" partnering with SciLifeLab in this pivotal work fills us with excitement," said Dr. Yuling Luo, Alamar Biosciences' Chairman, Founder, and CEO. "Our combined technologies will generate invaluable insights into protein expression and localization, greatly facilitating the validation of discoveries made utilizing the NULISA platform."
According to Professor Jochen Schwenk, SciLifeLab Group Leader and Platform Scientific Director of Proteomics, the partnership "represents a natural convergence for groundbreaking technology like the ARGO HT System. Thanks to SciLifeLab's expertise in affinity proteomics, extensive infrastructure, and partnership with the National Genomics Infrastructure, we anticipate enabling unprecedented levels of sensitivity, scalability, and integration in biomarker discovery."
Alamar Biosciences, a privately held life sciences company, marries its cutting-edge NULISA Platform and ARGO HT System with the latest advances in genomics to achieve single-digit attomolar detection sensitivity, outpacing other protein detection technologies currently on the market. To learn more, visit alamarbio.com.
SciLifeLab, Sweden's national center for molecular biosciences, unites academia, healthcare, and industry through shared infrastructure and data resources. With over 40 national infrastructure units and around 1,500 researchers, SciLifeLab is a leading hub for life science innovation and translational research. For additional information, please visit www.scilifelab.se.
This strategic alliance ramps up efforts to detect diseases at their earliest stages, paving the way for personalized medicine and more effective healthcare. As the collaboration progresses, it promises to unlock the doors to new levels of sensitivity, scalability, and integration in biomarker discovery.
- The collaboration between Alamar Biosciences and SciLifeLab, backed by the NULISA Platform and ARGO HT System, combined with SciLifeLab's extensive data resources and infrastructure, aims to advance sensitivity, scalability, and integration in biomarker discovery for medical-conditions.
- This partnership, driven by cutting-edge technology like the ARGO HT System, will potentially revolutionize health-and-wellness by propelling the early detection of diseases, contributing to personalized medicine and improved healthcare.
- Alamar Biosciences, with its proprietary NULISA Platform and ARGO HT System, partners with SciLifeLab, Sweden's national center for molecular biosciences, to leverage their shared technology and infrastructure for the development of new diagnostic tools related to science and technology.
- In a joint effort, Alamar Biosciences and SciLifeLab intend to scale up their research in the field of proteomics, utilizing cloud-based data resources, to transform the healthcare industry and the news surrounding it.
